AU2008294410B2 - Compounds with anti-cancer activity - Google Patents

Compounds with anti-cancer activity Download PDF

Info

Publication number
AU2008294410B2
AU2008294410B2 AU2008294410A AU2008294410A AU2008294410B2 AU 2008294410 B2 AU2008294410 B2 AU 2008294410B2 AU 2008294410 A AU2008294410 A AU 2008294410A AU 2008294410 A AU2008294410 A AU 2008294410A AU 2008294410 B2 AU2008294410 B2 AU 2008294410B2
Authority
AU
Australia
Prior art keywords
amino
compound
dione
trifluoromethyl
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008294410A
Other languages
English (en)
Other versions
AU2008294410A1 (en
Inventor
Yoko Hasegawa
Machiyo Ishigaki
Takumi Kawabe
Takuji Sato
Sayaka Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canbas Co Ltd
Original Assignee
Canbas Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canbas Co Ltd filed Critical Canbas Co Ltd
Publication of AU2008294410A1 publication Critical patent/AU2008294410A1/en
Application granted granted Critical
Publication of AU2008294410B2 publication Critical patent/AU2008294410B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2008294410A 2007-04-11 2008-04-11 Compounds with anti-cancer activity Active AU2008294410B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91125807P 2007-04-11 2007-04-11
US60/911,258 2007-04-11
PCT/IB2008/003036 WO2009031040A2 (en) 2007-04-11 2008-04-11 Compounds with anti-cancer activity

Publications (2)

Publication Number Publication Date
AU2008294410A1 AU2008294410A1 (en) 2009-03-12
AU2008294410B2 true AU2008294410B2 (en) 2012-09-06

Family

ID=39939984

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008294410A Active AU2008294410B2 (en) 2007-04-11 2008-04-11 Compounds with anti-cancer activity

Country Status (17)

Country Link
US (2) US8084454B2 (enExample)
EP (4) EP3567035B1 (enExample)
JP (2) JP5635396B2 (enExample)
KR (1) KR101475311B1 (enExample)
CN (2) CN101720323A (enExample)
AU (1) AU2008294410B2 (enExample)
BR (2) BR122022005149B1 (enExample)
CA (4) CA2913840C (enExample)
DK (2) DK3567035T3 (enExample)
ES (3) ES2594704T3 (enExample)
HU (2) HUE029370T2 (enExample)
IL (4) IL309201A (enExample)
MX (3) MX391154B (enExample)
NZ (1) NZ580237A (enExample)
RU (1) RU2482111C2 (enExample)
WO (1) WO2009031040A2 (enExample)
ZA (1) ZA200906960B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2913840C (en) * 2007-04-11 2019-03-05 Canbas Co., Ltd. Compounds with anti-cancer activity
WO2010006291A1 (en) 2008-07-10 2010-01-14 Nodality, Inc. Methods for diagnosis, prognosis and treatment
CN102405044A (zh) 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
US20100215644A1 (en) * 2009-02-25 2010-08-26 Nodality, Inc. A Delaware Corporation Analysis of nodes in cellular pathways
US8507734B2 (en) 2010-03-03 2013-08-13 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
EP2609064B1 (en) 2010-08-27 2016-09-28 Neonc Technologies Inc. Pharmaceutical compositions comprising derivatives of perillyl alcohol
US9211269B2 (en) 2010-12-17 2015-12-15 Neonc Technologies Inc. Methods and devices for using isoperillyl alcohol
WO2013020024A2 (en) * 2011-08-03 2013-02-07 Karyopharm Therapeutics, Inc. Maleimide compounds and methods of treatment
WO2013169600A1 (en) * 2012-05-09 2013-11-14 Delmar Pharmaceuticals Veterinary use of dianhydrogalactitol, diacetyldianhydrogalactitol, and dibromodulcitol to treat malignancies
ES2563861T3 (es) 2012-06-14 2016-03-16 Daiichi Sankyo Company, Limited Derivado de piperidinilpirazolopiridina
HK1215250A1 (zh) * 2013-01-30 2016-08-19 Bayer Pharma Aktiengesellschaft 氨基取代的异噻唑
US9540462B2 (en) 2014-12-05 2017-01-10 Massachusetts Institute Of Technology Catechol-rich polymers from N-substituted maleimides
DK3250550T3 (da) 2015-01-26 2023-07-17 Ottawa Hospital Res Inst Sammensætninger og fremgangsmåder til virussensibilisering
EP3261441B1 (en) 2015-02-12 2020-09-09 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
TW201808906A (zh) 2016-03-16 2018-03-16 拜耳作物科學股份有限公司 作為殺蟲劑之經取代吡啶化合物
USD801721S1 (en) 2016-03-31 2017-11-07 Patricia Grayson Briden Spooled item holding device
USD915100S1 (en) 2016-03-31 2021-04-06 Ocean 22, Llc Spooled item holding device
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
CN111867573A (zh) 2018-01-29 2020-10-30 科诺斯治疗学公司 硼替佐米的瘤内递送
EP3746451B1 (en) 2018-02-02 2023-07-12 Boehringer Ingelheim International GmbH Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors
MX2020007994A (es) 2018-02-02 2020-09-09 Boehringer Ingelheim Int Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat).
CA3225993A1 (en) 2018-02-08 2019-08-15 University Of Southern California The use of monoterpene, sesquiterpene, or their derivatives to permeabilize the blood brain barrier
EP4153600B1 (en) 2020-05-22 2024-08-07 Boehringer Ingelheim International GmbH Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
WO2021233882A1 (en) 2020-05-22 2021-11-25 Boehringer Ingelheim International Gmbh Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate
US20250017889A1 (en) * 2021-10-15 2025-01-16 The Curators Of The University Of Missouri Inhibitors of p1b-type atpases
CN114425054A (zh) * 2022-01-20 2022-05-03 中国人民解放军军事科学院军事医学研究院 一种蛋白酶体抑制剂Bortezomib在抗辐射损伤中的用途
CN120247782B (zh) * 2025-06-04 2025-08-19 北京颖泰嘉和生物科技股份有限公司 氟吡菌酰胺类化合物及其制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07244032A (ja) * 1994-03-01 1995-09-19 Ishikawajima Harima Heavy Ind Co Ltd 溶接部検査装置
WO1997009325A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US6476061B1 (en) * 1998-11-24 2002-11-05 Basf Aktiengesellschaft Fungicides containing pyrrolidones as their active agents
US6586369B1 (en) * 2000-02-26 2003-07-01 Basf Aktiengesellschaft Fungicidal agents containing pyrrolidones as their active agents and use thereof for treating plants
WO2005024755A2 (en) * 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes
WO2007053765A2 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
WO2008110891A2 (en) * 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5564557A (en) * 1978-11-08 1980-05-15 Mitsui Toatsu Chem Inc Diphenyl ether compound and herbicide containing the same
IL81307A0 (en) * 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
US5635966A (en) * 1994-01-11 1997-06-03 Hewlett-Packard Company Edge feed ink delivery thermal inkjet printhead structure and method of fabrication
JPH07224032A (ja) * 1994-02-09 1995-08-22 Mitsui Petrochem Ind Ltd Ｎ−アリールオキシフタルイミド誘導体、その製造方 法及びそれを有効成分として含有する除草剤
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
CA2245029A1 (en) * 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6205557B1 (en) 1998-06-09 2001-03-20 At&T Corp. Redundant call processing
CA2385257A1 (en) 1999-09-22 2001-03-29 Canbas Co., Ltd. Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents
JP2002318434A (ja) * 2001-04-23 2002-10-31 Konica Corp ハロゲン化銀写真感光材料、処理方法、および画像形成方法
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE520653T1 (de) * 2002-06-06 2011-09-15 Canbas Co Ltd Verbindungen, die den durch dna-schädigung induzierten g2-checkpoint des zellzyklus stilllegen und/oder die antikrebswirkung von dna- schädigenden behandlungen erhöhen
US7572816B2 (en) * 2003-08-01 2009-08-11 Auspex Pharmaceuticals, Inc. Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders
CA2558600C (en) * 2004-03-10 2013-07-09 Kureha Corporation A substituted-trialkyl amine compound with anti-viral activity based on antagonism against a chemokine receptor cxcr4
JP2008502595A (ja) * 2004-03-31 2008-01-31 エグゼリクシス， インコーポレイテッド 未分化リンパ腫キナーゼモジュレータおよびその使用方法
EP1851203A2 (en) * 2005-02-08 2007-11-07 Merck & Co., Inc. Inhibitors of checkpoint kinases
JP4976394B2 (ja) * 2005-08-17 2012-07-18 シェーリング コーポレイション 新規な高親和性のキノリンベースのキナーゼリガンド
WO2007114338A1 (ja) * 2006-03-31 2007-10-11 Takeda Pharmaceutical Company Limited 酸分泌抑制薬
CA2913840C (en) 2007-04-11 2019-03-05 Canbas Co., Ltd. Compounds with anti-cancer activity

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07244032A (ja) * 1994-03-01 1995-09-19 Ishikawajima Harima Heavy Ind Co Ltd 溶接部検査装置
WO1997009325A1 (en) * 1995-09-01 1997-03-13 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US6476061B1 (en) * 1998-11-24 2002-11-05 Basf Aktiengesellschaft Fungicides containing pyrrolidones as their active agents
US6586369B1 (en) * 2000-02-26 2003-07-01 Basf Aktiengesellschaft Fungicidal agents containing pyrrolidones as their active agents and use thereof for treating plants
WO2005024755A2 (en) * 2002-12-31 2005-03-17 Deciphera Pharmaceuticals, Llc. Medicaments for the treatment of neurodegenerative disorders or diabetes
WO2007053765A2 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
WO2008110891A2 (en) * 2007-03-09 2008-09-18 Orchid Research Laboratories Limited, New heterocyclic compounds

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PALANKI, M. et al, Bioorganic and Medicinal Chemistry Letters, 2000, 10(15), 1645-1648 *
PALANKI, M. et al, Bioorganic and Medicinal Chemistry Letters, 2003, 13(22), 4077-4080 *
YUKI, H et al, Chemical and Pharmaceutical Bulletin, 1967, 15(8), 1101-1106 *

Also Published As

Publication number Publication date
IL289165B2 (en) 2024-05-01
US20110092514A1 (en) 2011-04-21
MX2009011025A (es) 2010-01-25
ES2594704T3 (es) 2016-12-22
US20080275057A1 (en) 2008-11-06
KR101475311B1 (ko) 2014-12-23
CN101720323A (zh) 2010-06-02
IL289165A (en) 2022-02-01
CN105175394A (zh) 2015-12-23
WO2009031040A2 (en) 2009-03-12
AU2008294410A1 (en) 2009-03-12
IL309201A (en) 2024-02-01
EP2152692B9 (en) 2020-03-25
CA2913840A1 (en) 2009-03-12
EP3088397A1 (en) 2016-11-02
DK2152692T3 (en) 2016-09-26
EP4074704A1 (en) 2022-10-19
BRPI0810911A2 (pt) 2021-03-30
IL289165B1 (en) 2024-01-01
CA3030510A1 (en) 2009-03-12
CN105175394B (zh) 2018-06-08
EP3567035A1 (en) 2019-11-13
MX374896B (es) 2025-03-04
CA3188320A1 (en) 2009-03-12
RU2482111C2 (ru) 2013-05-20
CA2913840C (en) 2019-03-05
ES2732230T3 (es) 2019-12-12
HUE029370T2 (hu) 2017-02-28
BR122022005149B1 (pt) 2022-09-27
MX2020009403A (es) 2022-03-31
HUE059861T2 (hu) 2023-01-28
US8084454B2 (en) 2011-12-27
IL201380A0 (en) 2010-05-31
ZA200906960B (en) 2010-12-29
KR20090128560A (ko) 2009-12-15
CA2684037C (en) 2016-02-16
EP3567035B1 (en) 2022-06-01
US8415357B2 (en) 2013-04-09
BRPI0810911B1 (pt) 2022-05-17
JP2010523644A (ja) 2010-07-15
JP2014012706A (ja) 2014-01-23
DK3567035T3 (da) 2022-09-05
CA2684037A1 (en) 2009-03-12
EP2152692B1 (en) 2016-06-15
EP3088397B1 (en) 2019-04-10
RU2009141619A (ru) 2011-05-20
HK1139143A1 (zh) 2010-09-10
IL242883B (en) 2022-01-01
EP2152692A2 (en) 2010-02-17
WO2009031040A3 (en) 2009-05-14
CA3030510C (en) 2023-03-14
MX391154B (es) 2025-03-21
ES2927954T3 (es) 2022-11-14
JP5635396B2 (ja) 2014-12-03
NZ580237A (en) 2012-06-29

Similar Documents

Publication Publication Date Title
AU2008294410B2 (en) Compounds with anti-cancer activity
SK9622000A3 (en) Inhibition of raf kinase using aryl and heteroaryl substituted heterocyclic ureas
CN102459233A (zh) 二取代的酞嗪hedgehog途径拮抗剂
CN107176933B (zh) 一种含氮烷基化和芳基化亚砜亚胺的吲哚胺-2,3-双加氧酶抑制剂
WO2020125759A1 (zh) 作为wnt信号通路抑制剂的化合物及其医学应用
US11932638B2 (en) Ion channel inhibitor compounds for cancer treatment
JP2023503133A (ja) Ｃｄ７３を標的とするスルホンアミド化合物およびアデノシン受容体
CN118359627A (zh) 具有四环并环结构的mta协同性prmt5抑制剂化合物
CN111349093A (zh) 5,6-双环化合物作为wnt信号通路抑制剂及其医学应用
HK40083024A (en) Quinoline compounds with anti-cancer activity
CN116348114A (zh) 硫代苯并咪唑衍生物或其药学上可接受的盐及其用途
HK1139143B (en) Compounds with anti-cancer activity
CN116813560A (zh) 三唑酰胺类化合物及其制备方法和用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)